What is Zacks Research’s Forecast for CORT FY2026 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research increased their FY2026 earnings per share estimates for shares of Corcept Therapeutics in a research report issued on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $1.02 for the year, up from their previous estimate of $0.38. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.62 EPS, Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.51 EPS, FY2027 earnings at $1.91 EPS, Q1 2028 earnings at $0.41 EPS, Q2 2028 earnings at $1.17 EPS and FY2028 earnings at $4.07 EPS.

A number of other research firms also recently weighed in on CORT. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research report on Monday, July 27th. Piper Sandler restated an “overweight” rating and issued a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Stock Up 1.7%

Corcept Therapeutics stock opened at $121.05 on Friday. The company has a market capitalization of $13.09 billion, a PE ratio of 288.22 and a beta of 0.45. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $122.21. The firm’s fifty day moving average is $96.60 and its 200 day moving average is $64.19.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 earnings per share.

Insiders Place Their Bets

In other news, insider Sean Maduck sold 75,000 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the completion of the transaction, the insider owned 8,977 shares of the company’s stock, valued at approximately $588,801.43. The trade was a 89.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Atabak Mokari sold 80,000 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $114.71, for a total value of $9,176,800.00. Following the transaction, the chief financial officer directly owned 16,130 shares of the company’s stock, valued at $1,850,272.30. The trade was a 83.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 520,146 shares of company stock valued at $48,903,764 over the last 90 days. 20.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CORT. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics during the 3rd quarter worth $25,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Corcept Therapeutics in the second quarter valued at $27,000. Larson Financial Group LLC increased its stake in Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares during the last quarter. Gould Capital LLC raised its position in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 200 shares in the last quarter. Finally, Torren Management LLC purchased a new stake in Corcept Therapeutics during the fourth quarter valued at about $25,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Broad earnings-estimate increases: Zacks Research raised its EPS forecasts across multiple periods, including FY2026 to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also lifted, including Q1 2027 from a $0.17 loss to $0.11 earnings and Q2 2028 to $1.17 from $0.69. The revisions signal improving expectations for Corcept’s growth and profitability, though Zacks maintained a “Hold” rating.
• Positive Sentiment: Bullish growth thesis and analyst targets: An investment analysis rated CORT a “Strong Buy,” citing the launch of Lifyorli for platinum-resistant ovarian cancer, continued Korlym growth, projected revenue growth above 44%, and significant margin expansion. The analysis set one- and two-year price targets of $163 and $222, respectively. Recent Wall Street targets have also clustered well above the current trading level, including $164 from Truist and $165 from Piper Sandler and HC Wainwright. Corcept Therapeutics growth analysis
• Positive Sentiment: Strong recent operating results: Corcept’s latest quarterly report showed EPS of $0.36 versus the $0.02 consensus estimate and revenue of $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, reinforcing the case for upward estimate revisions.
• Neutral Sentiment: Valuation is demanding: Corcept has a market capitalization of approximately $13.1 billion and a reported price-to-earnings ratio above 288, leaving the stock sensitive to any slowdown in growth or disappointment in its pipeline.
• Negative Sentiment: Director sold a substantial stake: Director David Mahoney sold 103,606 shares for approximately $12.25 million, reducing his holdings by 8.37%. He still owns more than 1.13 million shares, but the transaction may weigh modestly on sentiment because it represents sizable insider selling. Corcept Therapeutics insider sale

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.